//
Work at this foundation?
Claim this profile to edit this page and see interest from grant seekers.
Center For Neurologic Study is a private corporation based in LA JOLLA, CA. The foundation received its IRS ruling in 1990. The principal officer is The Foundation. It holds total assets of $31.6M. Annual income is reported at $10.4M. The foundation is governed by 7 officers and trustees. Research: work undertaken at cns played a role in the introduction of interferon for the treatment of multiple sclerosis. The center participated in numerous national, experimental treatment trials involving amyotrophic lateral sclerosis, alzheimer's disease, neuropathy which led to the discovery of nuedexta which has been approved for use in the united states and europe. The drug has improved function in both alzheimer's disease and als patients, with study results published in major scientific journals. Pioneering work done at cns in collaboration with the university of california and ionis pharmaceuticals is widely belived to be the most promising strategy for treating neurodegenerative diseases such as huntington's disease and familial amyotrophic lateral sclerosis. This strategy involves the synthesis of small molecules that down regulate the expression of mutant proteins in the brain. The latter results were presented at the '18 annual meeting of the amer. Academy of neurology. Tax records are available from 2022 to 2023. According to available records, Center For Neurologic Study has made 6 grants totaling $110K, with a median grant of $5K. Individual grants have ranged from $200 to $50K, with an average award of $18K. The foundation has supported 3 unique organizations. Grants have been distributed to organizations in California and New York. Contributions to this foundation are tax-deductible.
No specific application information is available for this foundation. Check the 990-PF filings below for application guidelines, or visit the foundation's website if listed above.
Research: work undertaken at cns played a role in the introduction of interferon for the treatment of multiple sclerosis. The center participated in numerous national, experimental treatment trials involving amyotrophic lateral sclerosis, alzheimer's disease, neuropathy which led to the discovery of nuedexta which has been approved for use in the united states and europe. The drug has improved function in both alzheimer's disease and als patients, with study results published in major scientific journals. Pioneering work done at cns in collaboration with the university of california and ionis pharmaceuticals is widely belived to be the most promising strategy for treating neurodegenerative diseases such as huntington's disease and familial amyotrophic lateral sclerosis. This strategy involves the synthesis of small molecules that down regulate the expression of mutant proteins in the brain. The latter results were presented at the '18 annual meeting of the amer. Academy of neurology.
Expenses: $380K
Research: work undertaken at cns played a role in the introduction of interferon for the treatment of multiple sclerosis. The center participated in numerous national, experimental treatment trials involving amyotrophic lateral sclerosis, alzheimer's disease, neuropathy which led to the discovery of nuedexta which has been approved for use in the united states and europe. The drug has improved function in both alzheimer's disease and als patients, with study results published in major scientific journals. Pioneering work done at cns in collaboration with the university of california and ionis pharmaceuticals is widely belived to be the most promising strategy for treating neurodegenerative diseases such as huntington's disease and familial amyotrophic lateral sclerosis. This strategy involves the synthesis of small molecules that down regulate the expression of mutant proteins in the brain. The latter results were presented at the '18 annual meeting of the amer. Academy of neurology. Based on available records, the foundation has funded 6 grants. Its grantmaking reaches organizations primarily in CA, NY.
Center For Neurologic Study has distributed a total of $110K across 6 grants. The median grant size is $5K, with an average of $18K. Individual grants have ranged from $200 to $50K.
Center For Neurologic Study is a private foundation. To inquire about grants, you can look up the foundation using their EIN (953374771) on GuideStar or contact them directly. Many private foundations have specific application processes that may not be publicly listed.
Center For Neurologic Study is headquartered in LA JOLLA, CA. While based in CA, the foundation distributes grants to organizations across 2 states.
Track this funder — get alerted when new grants match
Get a free weekly digest of new grant opportunities as they're added to Granted. Unsubscribe anytime.
| Name | Title | Compensation | Benefits | Total |
|---|---|---|---|---|
| Richard Smith Md | PRESIDENT | $100K | $0 | $100K |
| Kathleen Myers | SECRETARY/TREASURER | $48K | $0 | $48K |
| Steven Bordner | DIRECTOR | $0 | $0 | N/A |
| David Louis Cutchin Phd | DIRECTOR | $0 | $0 | N/A |
| Randall Kaye Md | DIRECTOR | $0 | $0 | N/A |
| Cherryl Goldstein | DIRECTOR | $0 | $0 | N/A |
| Daryl Smith | DIRECTOR | $0 | $0 | N/A |
Total Giving
$679K
Total Assets
$26.4M
Fair Market Value
$26.4M
Net Worth
$26.4M
Grants Paid
$500
Contributions
$148K
Net Investment Income
$632K
Distribution Amount
N/A
Total: $25.8M
Total Grants
6
Total Giving
$110K
Average Grant
$18K
Median Grant
$5K
Unique Recipients
3
Most Common Grant
$50K
of 2022 grantees were first-time recipients
| Recipient | Location | Amount | Year |
|---|---|---|---|
| Uc San Diego FoundationTO FUND E2285 ALS RESEARCH | La Jolla, CA | $50K | 2022 |
| Target Als FoundationGENERAL SUPPORT | New York, NY | $5K | 2022 |
| Kennedy'S Disease AssociationTHE GREAT ROAD TRIP FUNDRAISER | Coarsegold, CA | $200 | 2022 |
MENLO PARK, CA
LOS ANGELES, CA
PALO ALTO, CA